Literature DB >> 24113482

Facial palsy complicated by masked otomastoiditis in a 3-month-old infant.

Xin-Chun Chen1, Chien-Wei Lu1, Chia-Hung Liu1, Chang-Ching Wei2.   

Abstract

BACKGROUND: The most common cause of facial palsy is idiopathic or Bell's palsy. Although uncommon in the postantibiotic era, otomastoiditis should receive more attention as a cause of facial palsy, especially in young children. Delay of identification and treatment may result in permanent neurological sequelae.
OBJECTIVES: To describe a 3-month-old infant eventually diagnosed with masked otomastoiditis with initial presentation of facial palsy. CASE REPORT: We report a case of facial palsy complicated by masked otomastoiditis in a 3-month-old male infant. The facial palsy completely recovered after parenteral antibiotics and myringotomy.
CONCLUSION: We use this case to emphasize that otomastoiditis should be considered in the differential diagnosis of young children with facial palsy. Diagnosis may be difficult as signs and symptoms of otitis media in young children are often nonspecific and subtle, particularly in infants. Early diagnosis and careful investigation of middle ear regions should be performed to avoid permanent sequelae.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diagnosis; facial palsy; otomastoiditis; treatment

Mesh:

Year:  2013        PMID: 24113482     DOI: 10.1016/j.jemermed.2013.08.029

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  2 in total

1.  Pediatric Acute Mastoiditis: Our Experience in a Tertiary Care Center.

Authors:  Inku B Shrestha; Monika Pokharel; Ashish Dhakal; Aakash Mishra
Journal:  Cureus       Date:  2021-05-16

2.  Infectious causes of peripheral facial nerve palsy in children-a retrospective cohort study with long-term follow-up.

Authors:  Cihan Papan; Leonie Kremp; Christel Weiß; Angela Petzold; Horst Schroten; Tobias Tenenbaum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.